Aug. 13 at 7:54 PM
$AUPH 🔥 Tang’s Chess Move: Why the PRESERVE Study is a "Heads AUPHy Wins, Tails Big Pharma Loses" Trap
Think about the sheer brilliance of Kevin Tang’s corporate strategy with the Phase 4 PRESERVE study. It is a single-arm trial testing Lupkynis combined with Big Pharma's top biologics (Benlysta, Gazyva, Saphnelo).Tang has backed Big Pharma into a corner where they cannot win, but AUPHy cannot lose:•
Scenario A (High Synergy): The combinations crush it. Lupkynis proves it dramatically accelerates healing when paired with biologics.
The Result: Big Pharma must acquire AUPHy to bundle the therapies, protect their franchises, and own the unified standard of care.•
Scenario B (Low/No Synergy): The combos add toxicity or fail to beat historical standalone Lupkynis data.
The Result: Overpriced biologics are exposed as useless add-ons. Lupkynis is validated as the undisputed apex monotherapy, crushing the "either/or" debate and forcing doctors straight to AUPHy.Pure boardroom warfare.
